Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 12
Submit an article Journal homepage
174
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

A rare case of autoimmune hemolytic anemia during venetoclax therapy for relapsed chronic lymphocytic leukemia

Christina HadjiaggelidouHematology Department, Theageneio Cancer Hospital of Thessaloniki, Thessaloniki, GreeceCorrespondence[email protected]
,
George DouganiotisHematology Department, Theageneio Cancer Hospital of Thessaloniki, Thessaloniki, Greece
,
Kyriaki TsirouHematology Department, Theageneio Cancer Hospital of Thessaloniki, Thessaloniki, Greece
,
Evgenia VerrouHematology Department, Theageneio Cancer Hospital of Thessaloniki, Thessaloniki, Greece
,
Theodora TriantafyllouHematology Department, Theageneio Cancer Hospital of Thessaloniki, Thessaloniki, Greece
,
Konstantina KeramidiotiHematology Department, Theageneio Cancer Hospital of Thessaloniki, Thessaloniki, Greece
,
Pavlina KonstantinidouHematology Department, Theageneio Cancer Hospital of Thessaloniki, Thessaloniki, Greece
&
Eirini KatodritouHematology Department, Theageneio Cancer Hospital of Thessaloniki, Thessaloniki, GreeceORCID Iconhttps://orcid.org/0000-0001-9404-807X
ORCID Icon show all
Pages 3054-3056 | Received 08 Apr 2021, Accepted 30 May 2021, Published online: 21 Jun 2021

References

  • Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood. 2010;116(23):4771–4776.
  • Crombie J, Davids MS. Venetoclax for the treatment of patients with chronic lymphocytic leukemia. Future Oncol. 2017;13(14):1223–1232.
  • Molica S, Polliack A. Autoimmune Hemolytic Anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy. Leuk Res. 2016;50:31–36.
  • De Back TR, Kater AP, Tonino SH. Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations. Expert Rev Hematol. 2018;11(8):613–624.
  • Vitale C, Salvetti C, Griggio V, et al. Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. Blood. 2021. doi: https://doi.org/10.1182/blood.2020008201.
  • Xu W, Li JY, Miao KR, et al. The negative prognostic significance of positive direct antiglobulin test in Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(9):1482–1487.
  • Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
  • Lampson BL, Davids MS. The development and current use of BCL-2 inhibitors for the treatment of chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2017;12(1):11–19.
  • Gentile M, Petrungaro A, Uccello G, et al. Venetoclax for the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017;26(11):1307–1316.
  • Korycka-Wolowiec A, Wolowiec D, Kubiak-Mlonka A, et al. Venetoclax in the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2019;15(5):353–366.
  • Morabito F, Gentile M, Seymour JF, et al. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target. Leuk Lymphoma. 2015;56(12):3250–3256.
  • Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, Phase 2 study. Lancet Oncol. 2016;17(6):768–778.
  • Davids MS, Hallek M, Wierda W, et al. Comprehensive safety analysis of Venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24(18):4371–4379.
  • Carriles C, Ordónez-Fernández C, Arias-Martínez A, et al. Autoimmune hemolytic anemia, adverse event to venetoclax. Farm Hosp. 2019;43(5):166–167.
  • Abdel-Samad N, Sughayar R. Can treatment with venetoclax for Chronic Lymphocytic Leukemia (CLL) result in autoimmune hemolytic anemia? Am J Case Rep. 2021;22(22):e928514.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.